Regorafenib treatment increases tumor infiltration of CD8+CXCR3+ T cells and inhibits tumor growth by upregulating C-X-C motif chemokine ligand 10 (CXCL10) expression in HCC cells, thereby improving survival rates [163]. Here, CD8A is linked to neoplasm.